ABBVIE Stock- J&J, others face California trial over opioid epidemic
(Reuters) — Four drugmakers were set to face trial Monday in a lawsuit by several large counties in California that are seeking more than $50 billion over claims the companies helped fuel an opioid epidemic by deceptively marketing addictive painkillers.
The case against Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Endo International PLC and AbbVie’s Allergan unit is one of the thousands of lawsuits by states and local governments seeking to hold pharmaceutical companies responsible for the drug crisis.
Opioids resulted in the overdose deaths of nearly 500,000 people from 1999 to 2019 in the United States, according to the U.S. Centers for Disease Control and Prevention.
The populous Santa Clara, Los Angeles and Orange counties and the city of Oakland accuse the companies of deceptively marketing painkillers in ways that downplayed their addictive risks. The drugmakers argue they acted appropriately and that they did not cause the epidemic.
If Orange County Superior Court Judge Peter Wilson finds the companies liable following a non-jury trial, the counties say the companies should have to pay $50 billion to cover the costs of abating the public nuisance they created, plus penalties.
More than 3,400 similar lawsuits are pending nationally over the opioid epidemic. The only other case to go to trial in the opioid litigation resulted in the state of Oklahoma in 2019 winning a $465 million judgment against J&J, which is appealing.
Other cases are slated to go to trial in the coming months, creating new pressure for the companies to reach settlements.
The nation’s three largest drug distributors — McKesson Corp., AmerisourceBergen Corp. and Cardinal Health Inc. — and J&J have proposed paying a combined $26 billion to resolve the cases against them. The proposed deal has not been finalized.